Entera Bio Ltd. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Entera completed a $275M private placement in July 2026 led by BVF Partners with participation from Longitude Capital, Vivo Capital, and others, bringing cash to $265.9M as of Q3 2026. The company expects to activate the first EB613 Phase 3 site in late 2026, enrolling ~900 postmenopausal women (600 EB613, 300 placebo), with topline results anticipated H2 2028. Four senior clinical executives were appointed (Chief Medical Officer, SVP Medical Affairs, VP Early Development, VP Clinical Development) and two board directors added effective December 1, 2026.
Why this rating
Capital raise of $275M is ~3.25× company's current market cap—transformational for funding Phase 3 through NDA submission (extending runway to 2030). De-risks trial execution with seasoned leadership. Moderate offset: $15.6M Q3 net loss (vs $3.2M prior year); $7.5M warrant remeasurement non-cash charge inflates burn rate perception.
Tradability signal
NO TRADE
No trade: positive news with only +0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.44% over 4 hrs, n=402). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.16 ▼ 1.25% | at our read · unknown $3.20 | +10 min · unknown $3.19 ▼ 0.47% | +30 min · unknown $3.23 ▲ 0.94% | +1 hr · unknown $3.29 ▲ 2.81% | +4 hrs · unknown $3.38 ▲ 5.47% |
The stock had already moved +1.27% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.